Phase 2 N=72 Deposition of Inhaled Prolastin in Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Change in Free Elastase in Induced Sputum From Baseline to Week 4 — -7.42; 6.11 ug/mL — p=0.197
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=28 An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy
Caries
Primary: % Surface Microhardness (SMH) Recovery Score Per Each of Five Arms — 20; 24; 22.5; 26.7 percent — p=0.0490
Phase 2 N=12 Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
Heart Failure, Congestive · Dilated Cardiomyopathy
Primary: Phase 2: Incidence of Treatment-emergent Adverse Events (TEAE) at 12 Months — 100; 100; 88.9; 92.9 percentage of participants
N/A N=58 Nutritional and Neurotransmitter Changes in PKU Subjects on BH4
Phenylketonuria
Primary: Change From Baseline in BMI at 12 Months — -0.65574 kg/m^2 — p=0.692782
Phase 3 N=111 Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
Primary: Stage 1: Percentage of Participants With an Overall Response According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL)…
N/A N=36 D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
Schizophrenia
Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) — 32.1; 33.0; 32.24; 33.8 t-scores
Phase 4 N=177 Cryptococcal Optimal ART Timing Trial
Cryptococcal Meningitis · HIV Infections · AIDS
Primary: Mortality — 40; 27 participants — p=0.03
N/A N=111 Evaluation of the Artus® CMV PCR Test
Cytomegalovirus Infections
Primary: a) CMV Viral Load — 100; 97.6; 86.36; NA percentage of agreement
N/A N=40 Global Effects of a Probiotic Strain on Lactating Women
Mastitis
Primary: Evidence of Clinically Definite Mastitis Confirmed by Microbiological Cultures and Somatic Cell Counts — 3.09; 2.90 log10 CFU/mL
Phase 2 N=79 A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
Multicentric Castleman's Disease
Primary: Percentage of Participants Who Achieved Durable Tumor and Symptomatic Response - by Independent Radiology Review — 0; 34 Percentage of participants — p=0.0012
Phase 3 N=538 Smoking-Cessation and Stimulant Treatment (S-CAST)
Cocaine Dependence · Methamphetamine Dependence · Nicotine Dependence
Primary: Stimulant-free Weeks Assessed by Self-report and Twice-weekly Urine Drug Screens — 77.7; 78.0 percentage of weeks
N/A N=339 MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms
Hot Flashes · Menopause · Vasomotor Disturbance
Primary: Frequency of Hot Flashes (Vasomotor Symptom [VMS] Frequency) -- Week 4 — 5.3; 5.1; 5.8 number of hot flashes per day
Phase 1 N=105 Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
Bacillus Anthracis (Anthrax) Infection
Primary: Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Vaccination (Day 0) — 11; 17; 13…
Phase 1 N=14 Does Pulmonary Rehabilitation Improve Balance in People With Respiratory Disease?
Lung Diseases
Primary: Standing Balance - Sway Path — 1.57; 3.40; 1.65; 2.59 cm/s
Phase 2 N=132 Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type II
Primary: Change From Baseline in Glycosylated Hemoglobin A1C (HbA1C) at the End of Each Treatment Period — -0.48; -0.46 percentage of HbA1C — p=0.3876